Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Carcinoma of the Head and Neck
NCT02769520Phase 2Active, not recruiting
- Start
- Jul 2016
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in squamous cell carcinoma of the head and neck (HNSCC). Started Jul 2016; status: active, not recruiting.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02769520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02769520.